Cardones Adela R, Banez Lionel L
Dermatology Branch, National Cancer Institute/NIH, 10 Center Drive, Rm 12N246, Bethesda, MD 20892, USA.
Curr Pharm Des. 2006;12(3):387-94. doi: 10.2174/138161206775201910.
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is thought to play a critical role in tumor growth and metastasis. Consequently, anti-VEGF therapies are being actively investigated as potential anti-cancer treatments, either as alternatives or adjuncts to conventional chemo or radiation therapy. Among the techniques used to block the VEGF pathway are: 1) neutralizing monoclonal antibodies against VEGF or its receptor, 2) small molecule tyrosine kinase inhibitors of VEGF receptors, 3) soluble VEGF receptors which act as decoy receptors for VEGF, and 4) ribozymes which specifically target VEGF mRNA. Recent evidence from phase III clinical trials led to the approval of bevacizumab, an anti-VEGF monoclonal antibody, by the FDA as first line therapy in metastatic colorectal carcinoma in combination with other chemotherapeutic agents. However, may challenges still remain, and the role of anti-VEGF therapy in the treatment of other solid tumors remains to be elucidated. The aim of this article is to review the progress of clinical investigations involving VEGF inhibitors in the treatment of different types of solid tumors.
血管内皮生长因子（VEGF）介导的血管生成被认为在肿瘤生长和转移中起关键作用。因此，抗VEGF疗法作为潜在的抗癌治疗方法正在被积极研究，可作为传统化疗或放疗的替代方法或辅助方法。用于阻断VEGF途径的技术包括：1）抗VEGF或其受体的中和单克隆抗体，2）VEGF受体的小分子酪氨酸激酶抑制剂，3）作为VEGF诱饵受体的可溶性VEGF受体，以及4）特异性靶向VEGF mRNA的核酶。III期临床试验的最新证据导致抗VEGF单克隆抗体贝伐单抗被FDA批准作为转移性结直肠癌的一线治疗药物，与其他化疗药物联合使用。然而，仍然存在许多挑战，抗VEGF疗法在其他实体瘤治疗中的作用仍有待阐明。本文的目的是综述涉及VEGF抑制剂治疗不同类型实体瘤的临床研究进展。
